Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs Ustekinumab in Pediatric IBD
NCT06742606Phase 1Not yet recruiting
- Sponsor
- Ain Shams University
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial in inflammatory bowel disease (IBD) comparing Adalimumab with Ustekinumab (2 arms). Primary endpoint: Induction of remission by histopathological remission using histological DCA scoring system at 48 weeks. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
adalimumabustekinumab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06742606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742606.